Arpeggio Biosciences, a Boulder, CO-based preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, and Builders VC, announced that it raised $17 million in Series A funding.
Builders VC led the round, which was also supported by Arpeggio's seed round investors: Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, and Fifty Years, as well as new participants Tencent, ATEM Capital, Formic Ventures, Tau Ventures, Milad Alucozai (BoxOne Ventures), and Matthew De Silva (Longtail Capital) (Longtail Capital).
The new capital will support the ongoing development of their drug pipeline targeting transcriptional mechanisms in disease.
“This Series A funding will enable us to continue our mission of discovering new therapies for diseases arising through dysregulation of transcription,” said Joey Azofeifa, Ph.D., Founder, and CEO of Arpeggio. “Our platform screens drug libraries for their effect on thousands of gene and non-coding transcripts, allowing for the first time, the design of molecules to modulate not just a single target but a cell’s entire transcriptome.”
Company: Arpeggio Biosciences, Inc.
Round: Series A
Funding Month: September 2022
Lead Investors: Builders VC
Additional Investors: Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, Fifty Years, Tencent, ATEM Capital, Formic Ventures, Tau Ventures, Milad Alucozai, and Matthew De Silva
Company Website: https://www.arpeggiobio.com/
Software Category: Preclinical Therapeutics
About the Company: Established in 2018, Arpeggio’s proprietary platform—developed by co-founders and Chief Executive Officer Joey Azofeifa, Chief Technology Officer Tim Read, and Chief Operating Officer Laura Norris—has built the largest database of nascent-RNA sequences in the world. Arpeggio's technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development. To date, Arpeggio has contracted with more than 40 pharmaceutical companies to assess the impact of diverse classes of molecules on cellular transcription.